• 1
    Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 26312639.
  • 2
    de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316322.
  • 3
    Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, et al.: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 19631969.
  • 4
    Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, et al.: Early prognostic usefulness of C-reactive protein added to the thrombolysis in myocardial infarction risk score in acute coronary syndromes. Am J Cardiol 2005; 96: 533537.
  • 5
    Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, et al.: Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 8291.
  • 6
    Hoffmann R, Suliman H, Haager P, Christott P, Lepper W, et al.: Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction. Atherosclerosis 2006; 186: 177183.
  • 7
    Mega JL, Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, et al.: B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction; an ENTIRE-TIMI-23substudy. J Am Coll Cardiol 2004; 44: 335339.
  • 8
    Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein and B-type natriuretic peptide. Circulation 2002; 105: 17601763.
  • 9
    Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, et al.; A to Z Investigators: Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005; 294: 28662871.
  • 10
    Niccoli G, Lanza GA, Spaziani C, Altamura L, Romagnoli E, et al.: Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 2007; 117: 306311.
  • 11
    Wilson RF, Laxson DD, Lesser JR, White CW: Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesion. Lancet 1989; 1: 807811.
  • 12
    Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, et al.; Academic Research Consortium: Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 23442351.
  • 13
    James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, et al.: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275281.
  • 14
    Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, et al.: Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41: 12641272.
  • 15
    Talwar S, Squire IB, Downie PF, Mccullough AM, Campton MC, et al.: Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21: 15141521.
  • 16
    Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, et al.: Plasma N-terminal pre-brain natriretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 19211929.
  • 17
    Grabowski M, Filipiak KJ, Karpinski G, Wretowski D, Rdzanek A, et al.: Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J 2004; 148: 655662.
  • 18
    Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, et al.; TYPHOON Investigators: Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 10931104.
  • 19
    Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, et al.: Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 11051113.
  • 20
    Robinson CR, Martin JL, Zhang L, Canham RM, Abdullah SM, et al.: Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction. Am J Cardiol 2006; 97: 79.
  • 21
    Ohman EM, Armstrong PW, White HD, Granger CB, Wilcox RG, et al.: Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. The GUSTO III Investigators Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 84: 12811286.